Vantage logo

Intellia proves its point

The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.

Vantage logo

Finding the next Prevail

An $880m buyout by Lilly shows that some gene therapy companies have not yet priced themselves out of the market.